Involved-field radiotherapy

RADIATION3 trials

Sponsors

Di Deng, Sun Yat-sen University, Yonsei University

Conditions

Recurrent Follicular LymphomaRecurrent Ovarian CancerTreatment Refusal

Phase 2

PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma

Sun Yat-sen UniversityTreatment Refusal

Start: 2016-02-29End: 2023-12-31Target: 35Updated: 2023-06-18

Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer

Yonsei UniversityRecurrent Ovarian Cancer

Start: 2018-05-10End: 2023-05-09Target: 107Updated: 2018-08-07

Phase 3

Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma

Di DengRecurrent Follicular Lymphoma

Start: 2015-10-31End: 2025-10-31Target: 166Updated: 2015-12-14

Related Papers

Phase II study of pegaspargase, etoposide, gemcitabine (PEG) followed by involved-field radiation therapy in early-stage extranodal natural killer/T-cell lymphoma

Hematology2024-09-131 citations